Clik here to view.
Engineered Bacteria Seen in Phase 1 Trial in Malignant Pleural Mesothelioma...
A new study, presented on April 14 at the European Lung Cancer Conference (ELCC) in Geneva, Switzerland, holds promise for the treatment of pleural mesothelioma. Results from a Phase 1b trial showed...
View ArticleClik here to view.
FDA Pauses Enrollment in Trials Testing Listeria as Therapy for Mesothelioma...
The U.S. Food and Drug Administration (FDA) has placed a partial hold on all clinical trials evaluating the LADD (Listeria-based immunotherapy construct) technology platform, pausing new patient...
View ArticleClik here to view.
Aduro Presents Positive Early Data from Phase 1b Mesothelioma Trial...
Combining the cancer vaccine CRS-207 with standard of care chemotherapy and cyclophosphamide looks like a promising first-line treatment for patients with unresectable malignant pleural mesothelioma,...
View ArticleAduro, Merck to Begin Clinical Trial Assessing CRS-207, Keytruda Combo to...
Aduro Biotech has expanded its collaboration with Merck to include an additional Phase 2 trial to test a combination of Aduro’s immunotherapy, CRS-207, with Keytruda (pembrolizumab) in patients with...
View ArticleFirst MPM Patient Dosed in Keytruda, CRS-207 Combo Phase 2 Trial, Aduro Says
Aduro Biotech has tested a novel combination treatment for malignant pleural mesothelioma (MPM) in the first patient of a Phase 2 trial (NCT03175172). MPM is the most prevalent form of mesothelioma...
View Article
